Cell-based production of viral particles has gain interest in the last years due to promising therapeutic applications. In the field of vaccination, novel vaccines are required to face the new pathogen outbreaks, and rapid and more efficient processes are required to respond as fast as possible to the vaccination demand worldwide. On the other hand, viral vector-driven gene therapies have demonstrated to be efficient and safe in numerous clinical trials, and three of them are already approved for commercialization. However, viral vector production is still a bottleneck in the road to the clinic. Although batch and fed-batch culture modes are preferred in industry, continuous culture strategies have demonstrated to improve viral titers and to reduce the bioprocessing costs. Therefore, there is increasing interest in exploring and optimizing continuous strategies in order to intensify viral vector production bioprocesses. This review is a summary of how continuous cultures have been applied to viral particle production (viral vaccines and viral vectors), the improvements achieved so far and the future perspectives in this field.

由于有前途的治疗应用，近年来基于细胞的病毒颗粒生产引起了人们的兴趣。在疫苗接种领域，需要新的疫苗来应对新的病原体爆发，并且需要快速和更有效的过程来尽可能快地响应全球的疫苗接种需求。另一方面，在许多临床试验中，病毒载体驱动的基因疗法已被证明是有效和安全的，其中三项已经被批准用于商业化。然而，病毒载体的生产仍然是通往临床的瓶颈。尽管分批和分批补料培养模式在工业中是首选的，但连续培养策略已证明可以提高病毒滴度并降低生物加工成本。所以，为了加强病毒载体生产的生物过程，人们对探索和优化连续策略的兴趣日益浓厚。这篇综述总结了如何将连续培养应用于病毒颗粒生产（病毒疫苗和病毒载体），迄今为止取得的进步以及该领域的未来前景。